ClinicalTrials.gg
Active, not recruitingNCT06051942Updated Jan 28, 2026

PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs

An interventional study of Robotic Waterjet Treatment in Benign Prostatic Hyperplasia and Localized Prostate Cancer, sponsored by PROCEPT BioRobotics. Active, not recruiting at 6 sites in 4 countries. Open to male participants aged Up to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by PROCEPT BioRobotics · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as active, not recruiting.
  • Registered 9 months after the study started (first participant enrolled Nov 2022, registered Sep 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
125
Allocation
Not applicable
Ages
Up to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 188 studies in Prostatic Hyperplasia with a site in United States — 29 open to participants now, 48 under way, none of them phase 3. Prostatic Hyperplasia · United States.

Enrollment
61st of 150
125 · median 83
Started
2022
with 9 others
No phase
63 of 188
13 open now
Primary completion
2026-07
later than 12 of 47 live
Registered
156th of 188
by date

Among the 188 studies in Prostatic Hyperplasia with a site in United States, this one is the 61st largest by enrollment of the 150 interventional ones that give a count, is one of 10 that started in 2022, is one of 63 with no phase, reaches primary completion later than 12 of the 47 other live ones, and was the 156th registered.

Prostatic Hyperplasia

831 studies on the registry are indexed under Prostatic Hyperplasia; 180 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

29 of the 188 studies in Prostatic Hyperplasia with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Prostatic Hyperplasia studies recruiting now, 70 (68%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: Up to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Prostatic Hyperplasia with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to assess the performance and safety of the AQUABEAM Robotic System for the resection and removal of prostate tissue in patients experiencing lower urinary tract symptoms (LUTS) and are diagnosed with localized prostate cancer. Participants will go through baseline and follow up assessments up to 12 months.

03

Conditions studied

  • Benign Prostatic Hyperplasia
  • Localized Prostate Cancer

Keywords

  • AQUABEAM
  • AQUABEAM Robotic System
  • Aquablation
  • Aquablation therapy
  • Robotic Waterjet Treatment
  • RWT
  • Prostate cancer
  • Lower urinary tract symptoms
  • LUTS
  • BPH
04

Who can participate

Ages eligible
Up to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • International Prostate Symptom Score (IPSS) ≥ 8
  • Gleason Grade Group 1-3
  • Prostate-specific Antigen (PSA) ≤20ng/mL
  • Cancer stage less than or equal to T2c

Exclusion criteria

Exclusion Criteria:

  • Patients with previous surgical treatment of benign prostatic hyperplasia
  • MRI evidence of extracapsular extension of cancer
  • Any severe illness that would prevent complete study participation or confound study results
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Aquablation

    Device: Robotic Waterjet Treatment

Interventions

  • DeviceRobotic Waterjet Treatment

    The Aquablation therapy is a minimally invasive, image-guided, heat-free robotic therapy delivered by the AQUABEAM Robotic System. During Aquablation therapy, the AQUABEAM Handpiece is inserted transurethrally into the prostatic urethra. The operating physician then utilizes cystoscopy in conjunction with transrectal ultrasound (TRUS) imaging for real time visualization. The AQUABEAM Robotic System utilizes high-velocity sterile saline waterjet to resect and remove the prostate tissue according to the operating physician's treatment plan.

    Also known as: Aquablation therapy

06

What researchers measure

Primary outcomes

  1. Incidence of Clavien-Dindo Adverse Events (Percentage of Participants) Through 3 Months Post Treatment

    Proportion (percentage) of participants with adverse events rated as related to the study procedure classified as Clavien-Dindo Grade 2 or higher or any Grade 1 event resulting in persistent disability (ejaculatory disorder, erectile dysfunction, or incontinence) evidenced through 3 months post-treatment.

    Time frame: 3 months post-treatment

07

Study locations

6 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Jul 2026, 44 months after the start.

Of 52 industry-sponsored interventional studies with no phase under Prostatic Hyperplasia, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 50. This study's planned 44 months is above that.

Counting every sponsor, half of 207 studies reached it within 27 months; a quarter within 15 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2023
First posted
Sep 25, 2023
StartActual
Nov 22, 2022
Primary completionEst.
Jul 2026
CompletionEst.
Mar 2027
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06051942
Lead sponsor
PROCEPT BioRobotics
Responsible party
Sponsor
First posted
Sep 25, 2023
Start date
Nov 22, 2022
Primary completion
Jul 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jan 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion